Andrew Hahn, MD, MD Anderson Cancer Center, presents a case of de novo metastatic prostate cancer with extensive bone and lung metastases and somatic BRCA2 loss, highlighting how molecular profiling can inform treatment intensification and individualized therapeutic decision-making.
Atish Choudhury, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts, presents a case of oligometastatic hormone-sensitive prostate cancer that highlights the integration of metastasis-directed therapy with intensified androgen deprivation and the evolving management of low-volume metastatic disease.
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Updated results from the phase 3 ECHO trial demonstrated that adding acalabrutinib to bendamustine and rituximab prolonged progression-free survival and delayed subsequent treatment in older patients with treatment-naïve mantle cell lymphoma,...
Updated results from the phase 3 ECHO trial demonstrated that adding acalabrutinib to bendamustine and rituximab prolonged progression-free survival and delayed subsequent treatment in older patients with treatment-naïve mantle cell lymphoma,...
Results from the ARROS-1 trial demonstrated that zidesamtinib produced high and durable systemic and intracranial response in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, supporting continued investigation of the...
Results from the ARROS-1 trial demonstrated that zidesamtinib produced high and durable systemic and intracranial response in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, supporting continued investigation of the...
An FDA advisory committee voted in favor of GRAIL’s Galleri multi-cancer early detection test for adults aged 50 years and older, supporting its safety, effectiveness, and overall benefit-risk profile as the agency continues review of its...
An FDA advisory committee voted in favor of GRAIL’s Galleri multi-cancer early detection test for adults aged 50 years and older, supporting its safety, effectiveness, and overall benefit-risk profile as the agency continues review of its...
Based on results from the REFOCUS trial, the FDA has approved lirafugratinib for previously treated patients with unresectable or advanced FGFR2-altered cholangiocarcinoma, providing an additional targeted treatment option for patients with...
Based on results from the REFOCUS trial, the FDA has approved lirafugratinib for previously treated patients with unresectable or advanced FGFR2-altered cholangiocarcinoma, providing an additional targeted treatment option for patients with...
The FDA approved Bravnetsa for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors, introducing a bioequivalent and therapeutically equivalent lutetium Lu 177 dotatate radioligand therapy through the abbreviated new drug...
The FDA approved Bravnetsa for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors, introducing a bioequivalent and therapeutically equivalent lutetium Lu 177 dotatate radioligand therapy through the abbreviated new drug...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
